Clinical inquiries. What is the best strategy for monitoring the lipid-lowering effects of medical therapy used for the primary prevention of coronary artery disease (CAD)?
Sherrod
J P
JP
University of North Carolina at Chapel Hill, USA.
Krist
A
A
D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000209:etiology* / Q000517:prevention & control*; D016903:Drug Monitoring / Q000379:methods* / Q000592:standards; D019317:Evidence-Based Medicine; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D011322:Primary Prevention / Q000379:methods*; D012307:Risk Factors; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D014280:Triglycerides